Next-generation sequencing and related tools are inching closer to the clinic. At the International Congress of Human Genetics meeting held last month in Montreal, Quebec, representatives from next-gen technology companies discussed near-term applications of their tools, including how they may be used in the clinic. "Right now, [sequencing] cost declined so fast in the last 12 months, it surprised us," said Martin Reese, co-founder and CEO of Omicia.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.